Education
About Us
Working with TipRanks
Follow Us
Genocea Biosciences (GNCAQ)
OTHER OTC:GNCAQ
GNCAQ Stock Chart & Stats
<$0.01
>-$0.01(-99.00%)
At close: 4:00 PM EST
<$0.01
>-$0.01(-99.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume1.07K
Average Volume (3M)N/A
Market Cap
$59.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-127.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding58,783,504
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNCAQ FAQ
What was Genocea Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Genocea Biosciences’s market cap?
Genocea Biosciences’s market cap is $59.00.
When is Genocea Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genocea Biosciences’s earnings last quarter?
Currently, no data Available
Is Genocea Biosciences overvalued?
According to Wall Street analysts Genocea Biosciences’s price is currently Overvalued.
Does Genocea Biosciences pay dividends?
Genocea Biosciences does not currently pay dividends.
What is Genocea Biosciences’s EPS estimate?
Genocea Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genocea Biosciences have?
Genocea Biosciences has 58,783,504 shares outstanding.
What happened to Genocea Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genocea Biosciences?
Currently, no hedge funds are holding shares in GNCAQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genocea Biosciences
Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Salarius Pharmaceuticals
―
PharmaCyte Biotech
―
Xenetic Biosciences
―
KALA BIO
―
Revelation Biosciences
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---